Cytori Therapeutics Inc (CYTX)

2.03
0.06 2.90
NASDAQ : Health Care
Prev Close 2.09
Open 2.07
Day Low/High 2.02 / 2.09
52 Wk Low/High 1.81 / 7.93
Volume 105.21K
Avg Volume 175.30K
Exchange NASDAQ
Shares Outstanding 20.49M
Market Cap 42.21M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytori Reports Second Quarter 2016 Business And Financial Results

Cytori Reports Second Quarter 2016 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its second quarter financial results and provided updates on its corporate activity and clinical development.

Cytori To Webcast Second Quarter Financial Results On August 4

Cytori To Webcast Second Quarter Financial Results On August 4

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Thursday, August 4, 2016 at 5:30 PM Eastern Time.

Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration

Cytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication of the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to...

Cytori ATHENA Trial For Chronic Ischemic Cardiovascular Disease

Cytori ATHENA Trial For Chronic Ischemic Cardiovascular Disease

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the results from the ATHENA Trials have been published and are now available online in Catheterization and Cardiovascular Interventions, a leading...

Cytori Cell Therapy Receives Limited Approval For Osteoarthritis In Japan

Cytori Cell Therapy Receives Limited Approval For Osteoarthritis In Japan

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that the use of Cytori Cell Therapy™ was approved for clinical use on June 24 th, 2016 to treat knee osteoarthritis at the Tokyo Osteoarthritis Clinic...

Cytori Closes Rights Offering For Gross Proceeds Of $17.1 Million

Cytori Closes Rights Offering For Gross Proceeds Of $17.1 Million

Cytori Therapeutics, Inc. ("Cytori" or the "Company") (NASDAQ: CYTX) announced today the closing of its rights offering ("Rights Offering") to subscribe for units at a subscription price of $2.

Cytori Announces Expiration Of Rights Offering And Estimated Gross Proceeds Of $17.1 Million

Cytori Announces Expiration Of Rights Offering And Estimated Gross Proceeds Of $17.1 Million

Cytori Therapeutics, Inc. ("Cytori" or the "Company") (NASDAQ: CYTX) announced today that the subscription period for its previously announced rights offering (the "offering") of units at a subscription price of $2.

Cytori Cell Therapy™ Leads To Improved Function And Reduced Scar Tissue In A Urinary Injury Model

Cytori Cell Therapy™ Leads To Improved Function And Reduced Scar Tissue In A Urinary Injury Model

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori Cell Therapy in a large...

Presentation Of Twelve Month Pilot Trial Data Of Cytori® Cell Therapy™ For ACL Reconstruction

Presentation Of Twelve Month Pilot Trial Data Of Cytori® Cell Therapy™ For ACL Reconstruction

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today Dr.

Cytori Announces Enrollment Completion In U.S. Phase III Scleroderma Trial

Cytori Announces Enrollment Completion In U.S. Phase III Scleroderma Trial

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced completion of enrollment for its U.

Cytori Extends Rights Offering Subscription Period To Friday, June 10, And Adjusts Unit Pricing

Cytori Extends Rights Offering Subscription Period To Friday, June 10, And Adjusts Unit Pricing

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has extended the subscription period and adjusted the subscription price for its previously announced rights offering until 5:00 PM Eastern Time on Friday,...

Cytori Announces Commencement Of Subscription Period For Previously Announced Rights Offering

Cytori Announces Commencement Of Subscription Period For Previously Announced Rights Offering

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares of common stock and warrants...

Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial

Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.

Cytori Informs Stockholders Of Key Dates Related To Announced Rights Offering

Cytori Informs Stockholders Of Key Dates Related To Announced Rights Offering

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today provided an informational update to stockholders regarding its recent rights offering and the key dates relative to the offering.

European Scleroderma Trial Investigating Cytori Cell Therapy To Be Presented In Japan

European Scleroderma Trial Investigating Cytori Cell Therapy To Be Presented In Japan

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use of Cytori Cell Therapy in the treatment of...

Cytori Reports First Quarter 2016 Business And Financial Results

Cytori Reports First Quarter 2016 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) ("Cytori" or the "Company") today announced its first quarter financial results and provided updates on its corporate activity and clinical development.

Cytori Granted Broad European Orphan Drug Designation

Cytori Granted Broad European Orphan Drug Designation

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the European Commission has granted orphan drug status to a broad range of Cytori Cell Therapy® formulations when used for the treatment of hand...

Cytori ATHENA Trial Results Support Symptomatic Benefit From Cytori Cell Therapy

Cytori ATHENA Trial Results Support Symptomatic Benefit From Cytori Cell Therapy

Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today the presentation of six and twelve month data from the ATHENA Trials at the annual meeting of The Society for Cardiovascular Angiography and Interventions.

Cytori Reports Preliminary Preclinical Data Supporting Use Of Cytori Cell Therapy™ For Both The Prevention And Treatment Of Hypertrophic Scars

Cytori Reports Preliminary Preclinical Data Supporting Use Of Cytori Cell Therapy™ For Both The Prevention And Treatment Of Hypertrophic Scars

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today presented preclinical data at the Annual Meeting of the American Burn Association (ABA) in Las Vegas showing the potential of Cytori's DCCT-10 cell therapy for...

Cytori To Webcast First Quarter Financial Results On May 10

Cytori To Webcast First Quarter Financial Results On May 10

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Tuesday, May 10, 2016 at 5:30 PM Eastern Time.

Cytori Announces Timing For Full Enrollment In U.S. Phase III Scleroderma Trial

Cytori Announces Timing For Full Enrollment In U.S. Phase III Scleroderma Trial

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.

Cytori Strengthens Global Patent Portfolio

Cytori Strengthens Global Patent Portfolio

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today a number of key additions to its patent portfolio in Japan and Europe.

Cytori Therapeutics To Present Preliminary Safety And Efficacy Preclinical Data At The 2016 American Burn Association Meeting

Cytori Therapeutics To Present Preliminary Safety And Efficacy Preclinical Data At The 2016 American Burn Association Meeting

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that data from preclinical studies showing potential for Cytori's DCCT-10 cell therapy product in the treatment of hypertrophic scarring (HTS), a common...

Cytori Update On Its U.S. Phase III Scleroderma Trial

Cytori Update On Its U.S. Phase III Scleroderma Trial

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.

Cytori Granted SME Status By European Medicines Agency

Cytori Granted SME Status By European Medicines Agency

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the European Medicines Agency's (EMA) Micro, Small and Medium-sized Enterprise (SME) office has granted SME status to Cytori Therapeutics.

Cytori Reports Fourth Quarter And Full Year 2015 Business And Financial Results

Cytori Reports Fourth Quarter And Full Year 2015 Business And Financial Results

Cytori Therapeutics (NASDAQ: CYTX) (Cytori or the "Company") today announced its fourth quarter and year-end 2015 financial results and provided updates on its corporate activity and clinical development.

Data Reports Sustained Benefit At Two Years With Single Administration Cytori Cell Therapy For Scleroderma

Data Reports Sustained Benefit At Two Years With Single Administration Cytori Cell Therapy For Scleroderma

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today reports new data demonstrating a single administration of Cytori Cell Therapy™ (ECCS-50) achieved a sustained improvement in hand dysfunction at two years in patients...

Cytori Management To Discuss Scleroderma Clinical Trial Findings

Cytori Management To Discuss Scleroderma Clinical Trial Findings

Cytori Therapeutics, Inc. (NASDAQ: CYTX) will host a live webcast to discuss the two year follow-up results from the SCLERADEC I trial for scleroderma.